Catalent (CTLT)

Executive Summary

Catalent is a leading global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceuticals, biologics, and consumer health products. Following its acquisition by Novo Holdings in early 2025, the company has transitioned to private ownership, though it continues to operate under the Catalent brand. The acquisition has strengthened Catalent's financial stability and strategic focus, particularly in high-growth areas such as GLP-1 receptor agonists and biologics. With a global network of facilities and advanced drug delivery technologies, Catalent is well-positioned to capture increasing demand from pharmaceutical innovators seeking outsourced development and manufacturing. The company's recent investments in expanding sterile injectable capacity and oral dose manufacturing are expected to drive revenue growth and operational efficiencies. However, integration risks and potential cultural clashes with Novo Holdings remain near-term challenges.

Upcoming Catalysts (preview)

• 2026Integration with Novo Holdings and realization of synergies80% success
• Q3 2026Capacity expansion for GLP-1 and sterile injectables85% success
• Q4 2026New long-term manufacturing contracts with top pharma companies60% success